High Purity Glycyl L Tyrosine and Cooling Tower Water Treatment Companies

Glycyl-L-Tyrosine, also identified by its molecular formula C11H14N2O4, is a dipeptide consisting of glycine and tyrosine. With a molecular weight of 238.2399, this compound exhibits a melting point between 278-285 °C (decomposition), signaling a stable crystalline structure when stored correctly. Its relative density of 1.362g/cm3 makes it a dense, manageable powder for precise weighing in laboratory settings.

The chemical identity is further defined by its EINECS number 211-525-1. In aqueous solutions (C=1%, H2O), the specific rotation [α] 20/D of +42±2° serves as a primary benchmark for optical purity. This precision is non-negotiable for pharmaceutical intermediates where chirality directly impacts biological activity. Ensuring the N-glycyl-L-tyrosine remains free from contaminants is paramount for those developing bioactive peptides or nutraceutical additives.

The utility of Glycyl-L-Tyrosine extends across several high-value sectors. In the pharmaceutical industry, it acts as a critical precursor for peptide synthesis. Because it combines the simplicity of glycine with the phenolic properties of tyrosine, it is often used in the development of agents targeting protein synthesis or enzymatic inhibition.

Beyond drug discovery, the cosmetic industry utilizes Glycyl-L-Tyrosine and related derivatives like Glycyl-L-Glutamine Monohydrate to enhance formulation stability and skin-penetration properties. Its role in peptide-based skincare focuses on biological signaling and antioxidant support. For manufacturers, the ability to source a consistent, high-purity grade ensures that the final consumer product maintains its intended biological activity without adverse reactions caused by impurities.

The stability of Glycyl-L-Tyrosine is highly dependent on environmental controls. To prevent degradation and maintain the specific rotation and melting point, the compound must be stored at -20 °C. This cold-chain requirement is a significant consideration for international logistics and warehouse management.

When procuring from overseas suppliers, buyers must evaluate the transporter's ability to maintain a constant temperature. Any fluctuation in the thermal environment can lead to the degradation of the N-hydrate form or the loss of optical purity. Professional procurement teams prioritize suppliers who provide detailed Certificates of Analysis (CoA) and utilize validated thermal packaging to ensure that the material arriving at the facility is identical to the material that left the laboratory.

Selecting a supplier for Glycyl-L-Tyrosine requires a shift from simple price-based procurement to quality-based evaluation. A reliable factory must demonstrate rigorous testing processes and quality assurance (QA) frameworks. This includes the use of High-Performance Liquid Chromatography (HPLC) to verify purity levels and Polarimetry to confirm the specific rotation.

Buyers should investigate the supplier's R&D capabilities. For instance, partnerships with academic institutions, such as Tsinghua University or Hebei University of Science and Technology, often indicate a commitment to improving production technology and reducing impurities. In the B2B chemical market, the ability to scale production while maintaining a narrow specification range is what separates world-class fine chemical enterprises from basic trading companies.

The trend in pharmaceutical intermediates is moving toward "Green Chemistry," where synthesis routes are optimized to reduce hazardous waste and energy consumption. For Glycyl-L-Tyrosine, this means developing more efficient enzymatic coupling methods that replace traditional chemical catalysts, leading to higher yields and fewer side products.

Furthermore, the integration of digital supply chain tracking is becoming standard. Real-time temperature logging during the transport of cold-chain chemicals ensures that the -20 °C requirement is met throughout the journey from the factory in China to laboratories in Europe or the Americas. This transparency reduces the risk of batch rejection and accelerates the R&D cycle for pharmaceutical innovators.